RiteMED Meloxicam

Symptomatic treatment of OA eg, arthrosis & degenerative joint disease, RA, ankylosing spondylitis, & similar conditions that respond to anti-inflammatory therapy. Pauciarticular or polyarticular juvenile idiopathic arthritis.

Adult OA, RA & ankylosing spondylitis Starting & maintenance dose: 7.5 mg once daily. Max: 15 mg once daily. Childn ≥2 yr Juvenile RA 0.125 mg/kg once daily. Max: 7.5 mg once daily.

May be taken with or without food: May be taken w/ meals if GI discomfort occurs.

Hypersensitivity. History of stroke (CVA), heart attack (MI), CABG, uncontrolled HTN & CHF NYHA II-IV. History of aspirin- or NSAID-induced asthma, urticaria or allergic reactions. Previous or active peptic ulcer. Perioperative pain in CABG surgery. Increased risk of serious GI adverse events including bleeding, ulceration, & perforation of the stomach or intestines.

Increased risk of CV thrombotic events, MI & stroke. Onset of new or worsening of pre-existing HTN; patients w/ fluid retention, HTN or heart failure; considerable dehydration. Monitor BP closely during initiation & throughout the course of therapy. Prior history of ulcer disease &/or GI bleeding. Other factors that increase the risk for GI bleeding include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, & poor general health status. Administration of NSAID may cause a dose-dependent reduction in prostaglandin formation & in renal blood flow which may precipitate overt renal decompensation. Patients at greater risk of are those w/ impaired renal function, heart failure, liver dysfunction, taking diuretics & ACE inhibitors. Administer w/ caution to patients w/ preexisting asthma. Discontinue use at the 1st appearance of skin rash, or any sign of hypersensitivity. Periodically determine Hg values in patients w/ initial Hg values of ≤10 g who are to receive a longer duration of therapy. Monitor patients who may be adversely affected by alterations in platelet function (eg, coagulation disorders or patients receiving anticoagulants). Do not use as corticosteroid substitute & for treatment of corticosteroid insufficiency. Discontinue treatment if clinical signs & symptoms consistent w/ liver disease develop or if systemic manifestations eg, eosinophilia or rashes occur. Not recommended in patients w/ advanced renal disease. Pregnancy & lactation. Childn ≤2 yr. Elderly.

Allergic & anaphylactoid reactions, face edema, fatigue, fever hot flushes, malaise, syncope, decrease/increase wt, household accident, edema, fall, flu-like symptoms. CV, GI, resp, neurologic, hematologic, urogenital & hepatic disorders. Arthralgia, back pain, dehydration, increased appetite. Dermatologic & sensitivity reactions. Abnormal vision, conjunctivitis, taste perversion, tinnitus.

Reduced effect of antihypertensive agents eg, ACE inhibitors, β-blockers & vasodilators. Increased clearance w/ bile acid sequestrants eg, cholestyramine. Increased rate of GI ulceration w/ aspirin & other NSAIDs. Increased nephrotoxicity of ciclosporin. Reduced natriuretic effects of furosemide & thiazides. Increased plasma lithium levels. Enhanced MTX toxicity. Increased risk of bleeding w/ oral anticoagulants (eg, warfarin), antiplatelet drugs, thrombolytics & systemic heparin.

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

M01AC06 - meloxicam ; Belongs to the class of non-steroidal antiinflammatory and antirheumatic products, oxicams.

Rx